Saama Technologies (Campbell, CA) has announced that it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium. The single goal, the company reports, is “to integrate data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50%.” Saama’s platform will allow researchers to dynamically visualize, analyze, and interrogate data across all available programs.
Suresh Katta, Founder and CEO of Saama Technologies, commented: “We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatments - and hopefully a cure - for SARS-CoV-2.”
David Shulkin, M.D., the Ninth Secretary, US Department of Veterans Affairs, added: “We won’t find rapid solutions for the SARS-CoV-2 pandemic with our data remaining so fragmented. In order to adequately address [it], we must share data from clinical studies across the research, healthcare, and pharma communities.”
Companies interested in joining the EndPandemic National Data Consortium to collaborate and accelerate solutions to the pandemic should contact Saama at endpandemic@saama.com or call 888.970.3550.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.